Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
March 28, 2026Molecular CancerOpen Access

SOS1: tracking the evolving path from promising to actionable therapeutic target in RAS-dependent cancers

View Full Paper
Ask AI
Bookmark
Share

Authors

LLLuis Luna-RamírezRGRosula Garcia-NavasESEugenio Santos

Discussion

Loading...

Member takes

Overview

This review evaluates SOS1 as a therapeutic target in RAS-dependent cancers, suggesting promising implications for treatment.

Key Points

  • The review aims to summarize the role of SOS1 as a therapeutic target in RAS-dependent cancers and explore its potential benefits and challenges.
  • Comprehensive evaluation of small-molecule SOS1 inhibitory drugs and SOS1 degraders.
  • Analysis of preclinical, in vitro, and in vivo model responses across tumor types.
  • Discussion of SOS1 inhibitors combined with RAS/MAPK pathway antagonists.
  • Overview of ongoing clinical trials on SOS1 inhibitors.
  • SOS1 is identified as a crucial therapeutic target due to its role in RAS-driven malignancies.
  • Inhibitors showcase specific therapeutic responses in various experimental models.
  • Combination therapies with SOS1 inhibitors exhibit promising synergistic effects.
  • SOS1 inhibition may help overcome resistance to FDA-approved RAS inhibitors.

Cite This Study

Luna-Ramírez et al. (2026) studied this question.

synapsesocial.com/papers/69c770888bbfbc51511e09cdhttps://doi.org/10.1186/s12943-026-02632-7
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Abstract 2080: SOS1 inhibition is an effective therapeutic strategy in SOS1-mutant cancer2024
  2. 2Identifying Potential SOS1 Inhibitors via Virtual Screening of Multiple Small Molecule Libraries against KRAS‐SOS1 Interface2024 · 1 citations
  3. 3Abstract 3313: Discovery of a potent, selective, and orally available small molecule for disruption of the SOS1-RAS interaction2024 · 2 citations
  4. 4The SOS1 Inhibitor MRTX0902 Blocks KRAS Activation and Demonstrates Antitumor Activity in Cancers Dependent on KRAS Nucleotide Loading2024 · 15 citations
  5. 5Discovery of CNS Penetrant SOS1 Inhibitors for the Treatment of KRAS-Dependent Cancers2026